Last 210.00 GBp
Change Today +6.00 / 2.94%
Volume 77.2K
SLN On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 11:05 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

silence therapeutics plc (SLN) Snapshot

Open
205.00 GBp
Previous Close
204.00 GBp
Day High
220.00 GBp
Day Low
192.50 GBp
52 Week High
02/25/14 - 388.75 GBp
52 Week Low
08/28/13 - 185.00 GBp
Market Cap
109.2M
Average Volume 10 Days
15.4K
EPS TTM
-0.20 GBp
Shares Outstanding
52.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SILENCE THERAPEUTICS PLC (SLN)

Related News

No related news articles were found.

silence therapeutics plc (SLN) Related Businessweek News

No Related Businessweek News Found

silence therapeutics plc (SLN) Details

Silence Therapeutics plc, a biotechnology company, discovers, develops, and delivers RNA interference (RNAi) therapeutics for the treatment of serious diseases primarily in North America and the Asia/Pacific. It has AtuRNAi, an RNAi platform, which encompasses the generation of potent chemically stabilized siRNA molecules. The company also has proprietary siRNA delivery technology platforms that comprise AtuPLEX, which delivers siRNA to the endothelial cells of the vascular system; DACC delivery system that delivers siRNA to the vascular endothelial cells of the lung; and DBTC delivery system, which delivers siRNA to hepatocytes and the hepatic vascular system of the liver parenchyma. Its products include Atu027, which is in a Phase IIa clinical trial for the treatment of pancreatic cancer, as well as in a Phase Ib clinical trial for head and neck cancer; Atu111 that is in pre-clinical stage for the treatment of lung diseases; and Atu112, which is in the pre-clinical stage for the treatment of systemic disorders. The company is also developing products for immunotherapy. Silence Therapeutics plc has partnership and collaboration agreements with various pharmaceutical companies, including Pfizer/Quark Pharmaceuticals, Novartis, AstraZeneca, Dainippon Sumitomo Pharma Co., Ltd., InteRNA Technologies B.V., Mirna Therapeutics Inc., and miRagen Therapeutics, Inc. The company is based in London, the United Kingdom.

38 Employees
Last Reported Date: 06/4/14

silence therapeutics plc (SLN) Top Compensated Officers

Chief Executive and Director
Total Annual Compensation: 70.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 119.0K GBP
Chief Operating Officer and Director
Total Annual Compensation: 58.0K GBP
Chief Medical Officer and Director
Total Annual Compensation: 53.0K GBP
Compensation as of Fiscal Year 2013.

silence therapeutics plc (SLN) Key Developments

Silence Therapeutics plc Announces Completion of Recruitment for Phase 2a Trial

Silence Therapeutics plc has completed the recruitment of patients for its Phase 2a trial of Atu027 in pancreatic cancer. Atu027 is Silence's short-interfering RNA (siRNA) therapy. It uses the Company's proprietary AtuPLEX® and AtuRNAi® technologies to broadly deliver siRNA to the endothelial cells of the vascular system, targeting the expression of the protein, PKN3, a key factor in cancer progression and metastasis. Silence has reached its enrolment target of 24 patients for its study, to be completed at clinics across Germany. The primary objective is to evaluate the safety and pharmacokinetics of Atu027 when used in combination with standard chemotherapy treatment, Gemcitabine, in subjects with locally advanced or metastatic pancreatic adenocarcinoma. Follow up analysis is expected in mid-2015.

Silence Therapeutics plc, Annual General Meeting, Jun 27, 2014

Silence Therapeutics plc, Annual General Meeting, Jun 27, 2014., at 14:00 GMT Standard Time. Location: 1 Lyric Square.

Silence Therapeutics plc Reports Unaudited Consolidated Earnings Results and Company Cash Flow Results for the Full Year Ended December 31, 2013

Silence Therapeutics plc reported unaudited consolidated earnings results and company cash flow results for the full year ended December 31, 2013. For the year, the company reported revenue of £117,000 against £163,000 a year ago. Operating loss was £9,072,000 against £26,314,000 for the same period in the last year. Finance income was £70,000 against £18,000 for the same period in the last year. Loss for the period before taxation was £9,002,000 against £26,284,000 a year ago. Retained loss for the period after taxation was £9,002,000 against £26,284,000 a year ago. Loss per ordinary equity share (basic and diluted) was 20 pence against 135 pence a year ago. Net cash outflow from operating activities £6,756,000 against £4,876,000 a year ago. Addition to property, plant and equipment was £120,000 against £3,000 for the same period in the last year. Addition to intangible assets was £18,000 against £199,000 for the same period in the last year. Financial income was higher at £70,000 (2012: £18,000) mainly due to higher average cash balances during the year. On the company basis net cash outflow from operating activities was £7,340,000 against £880,000 a year ago. Addition to property, plant and equipment was £5,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLN:LN 210.00 GBp +6.00

SLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.99 AUD -0.01
Galena Biopharma Inc $2.74 USD -0.10
Prosensa Holding NV $9.62 USD -0.25
Regulus Therapeutics Inc $6.20 USD -0.19
Tekmira Pharmaceuticals Corp C$14.10 CAD +0.26
View Industry Companies
 

Industry Analysis

SLN

Industry Average

Valuation SLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 838.9x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 924.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SILENCE THERAPEUTICS PLC, please visit www.silence-therapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.